Regulatory Ionis nets Zanvastro US approval in first for Alexander disease Pharmaceutical TechnologyIonis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease "in the coming weeks".Rare DiseaseRead full story pharminent September 4, 2026 (Last updated: September 7, 2026) Pharmaceutical Technology Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”. Rare Disease Read full story Post navigation Previous: Ivonescimab Beats Keytruda on Survival in China-Only Trial as Its Global Study StumblesNext: AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study Related Stories Regulatory FDA OKs Takeda, Protagonist drug for rare blood cancer pharminent August 31, 2026 Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026